Cargando…

LGG-21. FGFR1 GENE MUTATION AS A POTENTIAL RISK FACTOR FOR SPONTANEOUS INTRACRANIAL HEMORRHAGE IN PEDIATRIC LOW GRADE GLIOMA PATIENTS

The Fibroblast Growth Factor Receptor 1 (FGFR1) gene is the second most altered gene in pediatric LGGs and has been associated with poorer prognoses. A recent study suggested a link between the FGFR1 mutation and spontaneous intracranial hemorrhage in pediatric LGG patients, an event that can be det...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebert, Brittany, Campion, Stephani, Wagner, Aaron, Gonzalez-Vega, Maxine, Aguilar-Bonilla, Ana, Smith, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Low Grade Gliomas - LGG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260159/ http://dx.doi.org/10.1093/neuonc/noad073.230

Ejemplares similares

LGG-31. Pediatric low-grade gliomas with FGFR1 mutations and spontaneous hemorrhage: case series
por: Campion, Stephani, et al.
Publicado: (2022)

LGG-20. LANDSCAPE OF FGFR ALTERATIONS IN PEDIATRIC AND AYA GLIOMAS
por: Nobre, Liana, et al.
Publicado: (2023)

LGG-14. TREATMENT OF TWO PEDIATRIC FGFR-ALTERED LOW-GRADE GLIONEURONAL TUMORS WITH MEK INHIBITION
por: Lazow, Margot, et al.
Publicado: (2023)

LGG-22. CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT IN PEDIATRIC LOW-GRADE GLIOMA
por: Zahedi, Shadi, et al.
Publicado: (2023)

LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
por: Levine, Adrian, et al.
Publicado: (2023)

LGG-10. TREATMENT-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CHEMOTHERAPY FOR PEDIATRIC LOW-GRADE GLIOMA
por: Power, Phoebe, et al.
Publicado: (2023)

LGG-19. MULTI-MODALITY CHARACTERIZATION OF PEDIATRIC LOW-GRADE GLIOMA: THE ADDED VALUE OF DIFFERENT DATA MODALITIES
por: Haldar, Debanjan, et al.
Publicado: (2023)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

LGG-04. CLINICALLY RELEVANT MODELING OF FUSION-DRIVEN PEDIATRIC LOW GRADE GLIOMAS USING DROSOPHILA MELANOGASTER
por: Jung, Geena, et al.
Publicado: (2023)

LGG-05. IMAGING-BASED DEEP LEARNING FOR EVENT-FREE SURVIVAL PREDICTION IN PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA
por: Zapaishchykova, Anna, et al.
Publicado: (2023)

LGG-07. TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS; REAL WORLD DATA IN THE CONTEXT OF CONVENTIONAL TREATMENT MODALITIES
por: Sumerauer, David, et al.
Publicado: (2023)

LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAF(V600E) MUTATED PEDIATRIC LOW GRADE GLIOMAS
por: McThenia, Sheila, et al.
Publicado: (2023)

LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION
por: Nagabushan, Sumanth, et al.
Publicado: (2023)

LGG-17. EPIGENETICALLY DEFINED ANGIOCENTRIC GLIOMAS MAY LACK ANGIOCENTRIC GROWTH AND INSTEAD SHOW A VARIETY OF GROWTH PATTERNS
por: Stegat, Lotte, et al.
Publicado: (2023)

LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
por: Kilburn, Lindsay, et al.
Publicado: (2023)

LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-08. TARGETED THERAPY IN BRAF(V600E)-DRIVEN PEDIATRIC GLIOMAS: UNCOVERING MECHANISMS OF RESISTANCE THROUGH A MULTI-OMIC APPROACH
por: Capogiri, Monica, et al.
Publicado: (2023)

LGG-01. DEVELOPMENT OF A WEB-BASED CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERMSURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE
por: Munir, Faryal, et al.
Publicado: (2023)

LGG-06. DEVELOPMENT OF A WEB-BASED MOBILE DEVICE CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERM SURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION
por: Regal, Joshua, et al.
Publicado: (2023)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-15. SINGLE-NUCLEUS AND BULK RNA SEQUENCING OF PEDIATRIC PILOCYTIC ASTROCYTOMAS REVEALS CNS LOCATION-ASSOCIATED TUMOR CELL AND MICROENVIRONMENTAL HETEROGENEITY
por: Lammers, Julie A S, et al.
Publicado: (2023)

LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response
por: Morin, Eric, et al.
Publicado: (2022)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-44. PROGNOSTIC SIGNIFICANCE OF IMAGING CHARACTERISTICS IN PEDIATRIC LOW GRADE GLIOMAS
por: Baig, Muhammad, et al.
Publicado: (2020)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

LGG-02. PEDIATRIC LOW-GRADE GLIOMA RISK STRATIFICATION IN THE MOLECULAR ERA
por: Hata, Jessica, et al.
Publicado: (2021)

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas
por: Lindsay, Holly, et al.
Publicado: (2022)

LGG-59. Identifying hidden drivers of low-grade glioma tumor growth
por: Misek, Sean, et al.
Publicado: (2022)

LGG-20. Defining subgroups in low grade gliomas by their immune and stromal microenvironment
por: Körner, Meik, et al.
Publicado: (2022)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
por: Hanzlik, Emily, et al.
Publicado: (2021)

LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Barbour, Mustafa, et al.
Publicado: (2020)

LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
por: Nguyen, Tiffany, et al.
Publicado: (2020)

LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cj0gm0ajgdps73emiq9s4lqc51